$975.4M in CY2024 Part D spend98K claims · 15K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Ofatumumab used for?
Ofatumumab targets CD20-positive cells to treat certain lymphomas and autoimmune conditions.
Is there a generic for Ofatumumab?
No. Ofatumumab is brand-only with no generic equivalents currently in market.
How much does my plan pay for Ofatumumab?
Across 329 Part D plans, Ofatumumab averages $24459.32/unit (NADAC). Lowest available: $24459.32/unit. Highest in distribution: $24459.32/unit.
Is Ofatumumab on the FDA shortage list?
No. Ofatumumab is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.